Difference in the clinical outcome of bloodstream infections caused by *Klebsiella aerogenes* and *Enterobacter cloacae* complex

Minji Jeon¹, Kyungmin Huh¹*, Jae-Hoon Ko¹, Sun Young Cho¹, Hee Jae Huh², Nam Yong Lee², Cheol-In Kang¹, Doo Ryeon Chung¹, and Kyong Ran Peck¹

¹Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Irwon-dong, Gangnam-gu, Seoul 06351, Republic of Korea

²Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Irwon-dong, Gangnam-gu, Seoul 06351, Republic of Korea

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
*Corresponding author:*

Kyungmin Huh, MD, MSc

Division of Infectious Diseases, Department of Medicine

Samsung Medical Center, Sungkyunkwan University School of Medicine

81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea

Phone: 82-2-3410-0328, Fax: 82-2-3410-0064, E-mail: kyungminhuh.id@gmail.com
Synopsis

**Background:** The difference in clinical outcomes between *Klebsiella aerogenes* (formerly *Enterobacter aerogenes*) bacteremia (KAB) and *Enterobacter cloacae* complex bacteremia (ECB) is controversial.

**Objectives:** We compared the clinical outcomes of patients with KAB and ECB and examined the risk factors associated with mortality.

**Methods:** We conducted a retrospective case-control study of hospitalised patients with monobacterial KAB and ECB between January 2011 and June 2020. The primary outcome measure was 30-day all-cause mortality. Multiple logistic regression and propensity-score (PS) matching were used to identify independent risk factors for mortality. The models included demographic characteristics, comorbidities, recent healthcare contact, patient status at the onset of bacteremia, and severity of infection as covariates.

**Results:** A total of 282 patients with KAB or ECB were included, among whom 194 patients were selected after PS matching. The 30-day all-cause mortality rate was higher in the ECB group than in the KAB group (24.1% vs. 10.6%, *p* = 0.003). In a multivariable model, ECB was an independent risk factor for 30-day mortality in both overall and PS-matched cohorts (adjusted odds ratio, 3.528; 95% confidence interval, 1.614–7.714; *P* = 0.002). Stay in the intensive care unit at the onset of bacteremia and higher Pitt bacteremia score were found to be independent risk factors for 30-day mortality.

**Conclusion** In our study, mortality was significantly higher in patients with ECB than in those with KAB. Further studies are warranted to clarify the virulence mechanisms of *E. cloacae* complex.

Keywords: *Klebsiella aerogenes*, *Enterobacter cloacae* complex, bacteremia
1. Introduction

*Enterobacter* is a genus of Gram-negative, facultatively anaerobic, rod-shaped, non-spore-forming bacteria of the family Enterobacterales. *Enterobacter* species are associated with wound, intra-abdominal, respiratory, urinary, and bloodstream infections, representing an increasingly important nosocomial pathogen.¹ These species have intrinsic resistance to penicillin and early cephalosporin mediated by a chromosomal (*ampC*) beta-lactamase, and further resistance is rapidly induced upon exposure to beta-lactams, resulting in limited therapeutic options.²,³

Whole genome sequence-based bacterial phylogenetics demonstrated that *Enterobacter aerogenes* is more closely related to *Klebsiella pneumoniae* than other *Enterobacter* species. Therefore, the species formerly known as *E. aerogenes* was reclassified as *K. aerogenes*.⁴ However, the differences in clinical outcomes between infections caused by *K. aerogenes* and other *Enterobacter* species are unclear.

Some studies have suggested a difference in clinical outcomes between *K. aerogenes* bacteremia (KAB) and *Enterobacter cloacae* complex bacteremia (ECB). However, inconsistent results have been reported for the mortality of KAB and ECB in previous studies. In one study, there was no significant difference in overall in-hospital mortality between KAB and ECB; in contrast, bacteremia-related mortality was higher in KAB than ECB.⁵ However, another study reported that there was no significant difference in both all-cause mortality and bacteremia-attributable mortality.⁶

The purpose of this study was to compare the clinical outcomes of patients with KAB and ECB and to elucidate the risk factors associated with poor prognosis.
2. Methods

2.1. Study design and patient population

A retrospective, single-center, case-control study was conducted at the Samsung Medical Center, a tertiary-care hospital in the Republic of Korea. Study subjects included hospitalised adults (aged ≥18 years) who had at least one positive blood culture for *K. aerogenes* or *E. cloacae* complex between January 2010 and June 2020. Only the first episode of bacteremia in each patient during the study period was included. Patients with polymicrobial bacteremia or whose cultures were drawn in an outpatient setting were excluded. Each case of KAB was matched with one age- and sex-matched case of ECB, with priority to the temporally closest episode of bacteremia. This study was approved by the Institutional Review Board (IRB) of Samsung Medical Center (SMC, IRB No. 2020-12-096-001) with waiver of consent.

2.2. Microbiological methods

For species identification and antimicrobial susceptibility testing, a VITEK II automated system (bioMérieux, Marcy-l’Étoile, France) was used, utilizing a standard identification card and the modified broth microdilution method. Susceptibility was determined according to the recommendations of the Clinical and Laboratory Standards Institute guidelines. Intermediate susceptibility was considered as resistance. Phenotypic or genetic tests for extended-spectrum beta-lactamase production were not performed according to the routine protocol of our institution.
2.3. Data collection

We retrospectively collected the following data from medical records: age, sex, comorbid medical conditions, Charlson comorbidity index, source of infection, healthcare-associated acquisition, administration of immunosuppressive drugs, surgery within 3 months prior to the onset of bacteremia, and empirical and definitive antimicrobial regimens, duration of bacteremia, duration of susceptible antibiotic administration, susceptibility to antibiotics, and source control procedure. Other conditions when the blood culture was taken were also reviewed, including presentation with septic shock, Pitt bacteremia score, presence of an indwelling catheter, mechanical ventilation, tracheostomy, and haemodialysis. The primary outcome measure was 30-day all-cause mortality. The secondary outcome measure was the infection-attributable mortality at 30 days. Additionally, the clinical response after 14 days was assessed.

2.4. Definition

Healthcare-associated infection was defined as bacteremia that occurred ≥48 hours after admission, ≤2 weeks after discharge, or that occurred in patients with prior healthcare contact. Prior healthcare contact is defined as the presence of the following in the preceding 3 months: hospitalisation for more than 2 days, residence in a nursing home or other long-term care facilities, receipt of home infusion therapy or home wound care, and chronic dialysis. Active cancer was defined as any type of cancer (except basal cell or squamous cell carcinoma of the skin, or primary brain tumor) that met at least one of the following: diagnosis within 6 months before the onset of bacteremia, receiving anticancer treatment at the time of bacteremia, any treatment for cancer during the 6 months before bacteremia, or recurrent locally advanced or metastatic cancer. The administration of immunosuppressive drugs was defined as exposure to doses greater than the equivalent of 20 mg prednisone per day for more than 14 days or antineoplastic chemotherapy within the previous month. Prior antibiotic exposure was defined as exposure to antibiotics within 90 days prior to the onset of bacteremia. Septic shock was
defined as sepsis with systolic blood pressure <90 mmHg that did not respond to adequate fluid resuscitation and required the use of a vasopressor.\textsuperscript{13} Patients without any identifiable source of infection were classified as having primary bacteremia. Catheter-related infections were defined using guidelines from the Infectious Disease Society of America (IDSA).\textsuperscript{14}

Empirical antibiotic therapy was defined as initial antibiotic therapy started within 24 h after blood culture. Definitive antibiotic therapy was defined as antibiotics administered within 24 h after the result of blood culture, and antibiotic susceptibility tests have been reported. Antibiotic therapy was considered appropriate if the isolate was susceptible to any of the antibiotics administered at the optimal doses and route of administration. The duration of antibiotic therapy was defined as the period of administration of susceptible antibiotics from the date of initial positive blood culture. Source control was defined as an adequate removal or drainage of the focus of infection, which included removal of the indwelling catheter in catheter-related infection, insertion of a percutaneous urinary catheter, percutaneous or endoscopic biliary drainage, and percutaneous drainage/aspiration of abscess. Primary bacteremia or urinary tract infection that did not require such intervention was considered to have controlled the source.

Clinical response was classified as complete response (resolution of fever, bacteremia, and all other signs of infection), partial response (improvement of the above, but not complete resolution), and treatment failure (persistent fever or bacteremia, clinical deterioration, or death). Mortality attributable to bacteremia was defined as death with positive blood cultures for \textit{K. aerogenes} or \textit{E. cloacae} complex or persistent signs or symptoms of infection, but no other definitive causes of death. The duration of bacteremia was calculated only in cases where follow-up blood cultures were taken within 72 h after the initial positive culture, as the time interval from the initial positive culture to the first negative culture.
2.5. Statistical analysis

Categorical variables were compared using Pearson’s chi-squared test or Fisher’s exact test. Continuous variables were compared as the mean ± standard deviation or median (interquartile range) using a two-sample Student’s t-test or the Mann–Whitney U test. The crude 30-day all-cause mortality of patients with KAB and ECB was compared using the Kaplan-Meier curve with a log-rank test.

A multiple logistic regression model was used to identify independent risk factors associated with mortality in patients with KAB and ECB in both the original and propensity score (PS)-matched cohorts. Variables with a P-value less than 0.20, in the univariable analysis, were subjected to further selection using a backward logistic procedure.

PS matching was conducted to further mitigate the differences in baseline characteristics between patients with KAB and those with ECB (Supplementary Table 1). Each PS was calculated using a multivariable logistic regression model in which the dependent variable was a binary indicator of KAB or ECB. Covariates with a P-value <0.2, as determined by univariate analysis, were used to generate the PS, which included underlying renal disease, administration of immunosuppressive therapy or corticosteroids within 30 days, active cancer, intensive care unit care, healthcare-associated infection, primary bacteremia, and urinary tract infection. Additionally, age and sex were included in the matching variables, considering the possibility of imbalance after PS matching. We performed 1:1 greedy matching with a calliper of 0.2. The standardised mean difference of covariates was tested to ensure balance after PS matching between the KAB and ECB groups (Supplementary Figure 1).

All tests were two-tailed, and a P-value <0.05 was considered statistically significant. Statistical analysis was performed using SPSS (version 25.0; IBM, Armonk, NY) and SAS (version 9.4; SAS Institute, Cary, NC).
3. Results

3.1. Study population

A total of 682 patients with monomicrobial KAB (n=141) or ECB (n=541) were identified during the study period; of these, 282 patients were included in the analysis after 1:1 age- and sex-matching. The PS-matched cohort included 194 patients.

The baseline characteristics of patients with KAB or ECB in the overall and PS-matched cohorts are summarized in Table 1. Active cancer was the most common underlying disease in both groups (KAB, 70.9% vs. ECB, 78.0%). Patients with ECB were more likely to have underlying renal disease, administration of immunosuppressive therapy or corticosteroids. Healthcare-associated acquisition of bacteremia was more likely to occur in patients with ECB (KAB, 71.6% vs. ECB, 83.0%; p=0.023). In terms of the focus of infection, hepatobiliary infection was the most common in both groups.

Primary bacteremia was more commonly associated with ECB. Urinary tract infection was more commonly associated with KAB. There were no significant differences in the appropriateness of empirical or definitive antimicrobial treatment, septic shock, Pitt bacteremia score, or source control.

Resistance rates to antibiotics were similar in the two groups, except for imipenem (KAB, 27.0% vs. ECB, 12.1%, p=0.002) and ciprofloxacin (KAB, 2.8% vs. ECB, 9.2%, p=0.021). During the entire study period, the rate of resistance to third-generation cephalosporins and imipenem was higher in the KAB group (see Supplementary Table 2). In terms of definitive antibiotics, third-generation cephalosporins and carbapenems were similarly used in both groups (see Supplementary Table 3).

In the PS-matched cohort, 97 pairs of patients with KAB and ECB were included. The standardised mean differences were less than 10% after matching (see Supplementary Figure 1). There were no significant differences between the KAB and ECB groups in baseline characteristics, except for resistance rate to cefepime, imipenem, and ciprofloxacin.
3.2. Clinical outcomes and risk factor of 30-day mortality

Clinical outcomes of the KAB and ECB groups in both the overall and PS-matched cohorts are presented in Table 2. The 30-day all-cause mortality was significantly higher in the ECB group (24.1%) than in the KAB group (10.6%, p=0.003) in the overall cohort. In the PS-matched cohort, the 30-day all-cause mortality was higher in the ECB group (24.7%) than in the KAB group (11.3%, P=0.015). Kaplan-Meier survival analysis also revealed that the ECB group had higher mortality than the KAB group in both cohorts (Figure 1). In a multivariable model, ECB was an independent risk factor for mortality both in overall (adjusted odds ratio [aOR], 3.528; 95% confidence interval [CI], 1.614–7.714; P=0.002) and PS-matched cohorts (aOR, 4.135; 95% CI, 1.619–10.558; P=0.003; Table 4). Infection-attributable mortality of ECB group was also marginally higher than those of KAB group in overall cohort (KAB, 4.3% vs. ECB, 9.2%, p=0.096). There were no significant differences in the length of hospital stay, length of stay in the intensive care unit, or treatment failure by day 14 between the overall and PS-matched cohorts. The duration of bacteremia was similar in the PS-matched cohort (median, 2 days; P=0.661).

The baseline characteristics of patients according to survival at 30 days after positive blood culture are presented in Table 3. The inappropriateness of definitive antibiotics was marginally associated with 30-day mortality in the original cohort (p=0.055), but no significant association was observed after matching (P=0.637). The variables associated with 30-day all-cause mortality both before and after matching were ECB, presence of urinary catheter, stay in the intensive care unit at the onset of bacteremia, dialysis, healthcare-associated infection, septic shock at presentation, and a higher Pitt bacteremia score. Source control did not show a significant association with mortality in our study. In addition, there were no significant differences in prognosis between infections with easily controllable sources (such as catheter-related infection and urinary tract infection) and infections requiring invasive source control. In a multivariable model, stay in the intensive care unit at the onset of
bacteremia and higher Pitt bacteremia scores were also independent risk factors for 30-day mortality in both the overall and PS-matched cohorts.

The causes of death are summarised in Supplementary Table 4. Infection-attributable mortality was higher in the ECB group, although the difference was not significant. In a multivariable model of the overall cohort, ECB was associated with 30-day infection-attributable mortality (aOR, 3.562; 95% CI, 1.007–12.600; \(P=0.049\)). However, after PS matching, ECB was not associated with the secondary outcomes. Administration of immunosuppressive therapy or corticosteroids and the inappropriateness of definitive antibiotics were independent risk factors for 30-day infection-attributable mortality (Supplementary Table 5).

4. Discussion

We found that the 30-day all-cause mortality in the ECB group was higher than that in the KAB group. The infection-attributable mortality of the ECB group tended to be higher than that of the KAB group, although the difference was not statistically significant.

These findings are different from those of previous studies on Enterobacter species bloodstream infections. A previous study reported that the 28-day mortality was higher in KAB than in ECB (KAB, 14.9% vs. ECB, 8.1%).\(^5\) Another previous study reported that in-hospital mortality was 28% in the KAB group and 21% in the ECB group.\(^6\) In our study, the 30-day all-cause mortality was 14.6% in the KAB group and 24.3% in the ECB group.

Several factors may have influenced these differences. First, there were differences in the severity of infection and the proportion of appropriate antibiotic therapy by species in different studies. Song et al. reported that KAB commonly presented as septic shock and was associated with a higher rate of bacteremia-related mortality than ECB.\(^5\) However, these investigators did not compare the appropriateness of empirical antibiotic therapy. Appropriate empirical antibiotic therapy is one of the most critical factors in the outcome of bloodstream infection; therefore, unobserved differences in the
appropriateness of empirical antibiotic therapy might have influenced the results of the study. In this study, a lower proportion of KAB patients received appropriate overall antimicrobial therapy (ECB, 92.4% [159/172] vs. KAB, 85.1% [57/67], P=0.083). The authors showed that patients who died within 24 h after the onset of bacteremia did not receive adequate antibiotics and explained that most KAB patients with fatal outcomes (died in the early phase after bacteremia) were classified as being given inappropriate antibiotics. In our study, the proportion of septic shock at the time of bacteremia and Pitt bacteremia score were similar between the KAB and ECB groups, and the ECB group had a worse outcome. This was different from previous studies which reported that the proportion of septic shock was higher in the KAB group than in the ECB group.\textsuperscript{5,6} This difference suggests the possibility that the severity of the infection itself, rather than species, influenced the outcome.

Second, the difference in baseline characteristics between the study cohorts may have resulted in differences in mortality. For example, in a previous study that reported that KAB was associated with poor clinical outcomes, the median age and the proportion of healthcare-associated infections were higher in the KAB group.\textsuperscript{6} Although the difference was not statistically significant, the study might have been underpowered to detect such differences. In addition, more cases with ECB were caused by catheter-related infection and urinary tract infection, which are known to be associated with better outcomes.\textsuperscript{15,16} We performed PS matching to mitigate baseline imbalances in characteristics that are likely to affect the outcome, and no variables showed significant differences between the KAB and ECB groups after matching.

The higher mortality in the ECB in this study may have been attributed to the virulent potential of \textit{E. cloacae} complex. \textit{Enterobacter} species harbour a variety of virulence mechanisms, including heavy metal resistance, efflux pumps that result in a wide array of antimicrobial resistance, and additional siderophore assembly kits to gain a fitness advantage that facilitates their survival in diverse environments.\textsuperscript{17,18} Flynn et al. prospectively studied \textit{Enterobacter} colonization in cardiac surgery patients receiving cefazolin prophylaxis.\textsuperscript{19} \textit{E. cloacae} was isolated four times more frequently than \textit{K. aerogenes}, and it led to invasive infections more often than \textit{K. aerogenes}. This result suggests that the virulence factor, such as fitness, of \textit{E. cloacae} increases the infection rate and results in a poor
prognosis. According to studies on virulence gene detection in *Enterobacter* species in Italy, Iraq, and Egypt, several virulence genes encoding siderophores and adhesins were detected in *E. cloacae* isolates. These findings are different from those of a previous study in Brazil, which reported that virulence genes were detected only in *K. aerogenes* isolates, whereas no *E. cloacae* isolate harboured virulence genes. Considering the characteristics of *Enterobacter* species that can acquire plasmid-mediated antibiotic resistance genes, the epidemiology of virulent genes may vary depending on regional characteristics, so the detection rate of virulence genes may differ between countries. Thus, it is necessary to study the molecular epidemiology of virulence genes of *E. cloacae* complex isolates and *K. aerogenes* isolates from various countries.

In our study, the use of antibiotics with *in vitro* susceptibility was defined as appropriate even when third-generation cephalosporins were used. There is a controversy about the optimal antibiotic therapy for infections caused by AmpC producing organisms. The emergence of resistance against broad-spectrum cephalosporins during treatment have been reported, but whether the treatment with a third-generation cephalosporin is associated with poor outcome remains controversial. Various studies reported comparable outcomes between broad-spectrum cephalosporins and carbapenems. We analyzed the clinical outcome by specific antibiotic agents using our dataset. The 30-day all-cause mortality in the overall cohort was 12.0% (3/25, \( p = 0.588 \)) in the patients who were treated with third-generation cephalosporin and 21.8% (17/78, \( p = 0.226 \)) in those with carbapenem. In the PS-matched cohort, the use of carbapenem as a definitive antibiotic was an independent risk factor associated with mortality. Surely this difference is likely to be due to the severity of infection rather than the weaker efficacy of carbapenem, but our results do not show that the use of third-generation cephalosporin is associated with poor outcomes. Furthermore, the proportion of patients who were treated with third-generation cephalosporins was low (8.9% in the overall cohort and 9.2% in the PS-matched cohort).

Our study has several limitations. First, since our study was conducted at a single tertiary-care center, the results may not be generalizable. Second, the study was performed retrospectively. Although we tried to control for confounders using PS matching and multiple logistic regression, the possibility of
bias by unobserved variables cannot be excluded. In addition, among 682 patients with KAB or ECB who were initially screened, only 282 were included after age- and sex-matching. There thus remains a possibility that an unobserved bias was introduced during matching. However, we only used age, sex, and temporal proximity to cases with KAB for initial matching. Consequently, there was no significant difference in the 30-day all-cause mortality between the patients with ECB who were initially identified (112/541, 20.7%) and those who were included in the analysis (34/141, 24.1%; p=0.381), suggesting that the risk of selection bias is low. Third, only bloodstream infections were included in our study. Therefore, the results may not be applicable to localised infections without bacteremia.

In conclusion, ECB was independently associated with higher 30-day all-cause mortality than KAB. Further studies are warranted to clarify the virulence mechanisms of *E. cloacae* complex.
Acknowledgments

None

Funding

This work was supported by the Ministry of Education through the National Research Foundation of Korea (grant number NRF-2018R1D1A1B07048350).

Potential conflict of interest

All no conflict

Patient consent statement

This study was approved by the Institutional Review Board (IRB) of Samsung Medical Center (IRB No. 2020-12-096-001) with waiver of consent.
Figure legend

Figure 1. A survival curve of the patients with *Klebsiella aerogenes* and *Enterobacter cloacae* complex bacteremia. (A) Overall cohort, (B) propensity score-matched cohort.
Reference

1. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. *J Antimicrob Chemother* 1992;29 Suppl A:19-24.

2. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. *Ann Intern Med* 1991;115:585-90.

3. Choi SH, Lee JE, Park SJ, Choi SH, Lee SO, Jeong JY, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. *Antimicrob Agents Chemother* 2008;52:995-1000.

4. Tindall BJ, Sutton G, Garrity GM. Enterobacter aerogenes Hormaeche and Edwards 1960 (Approved Lists 1980) and Klebsiella mobilis Bascomb et al. 1971 (Approved Lists 1980) share the same nomenclatural type (ATCC 13048) on the Approved Lists and are homotypic synonyms, with consequences for the name Klebsiella mobilis Bascomb et al. 1971 (Approved Lists 1980). *Int J Syst Evol Microbiol* 2017;67:502-4.

5. Song EH, Park KH, Jang EY, Lee EJ, Chong YP, Cho OH, et al. Comparison of the clinical and microbiologic characteristics of patients with Enterobacter cloacae and Enterobacter aerogenes bacteremia: a prospective observation study. *Diagn Microbiol Infect Dis* 2010;66:436-40.

6. Wesevich A, Sutton G, Ruffin F, Park LP, Fouts D, Fowler VG, Jr., et al. Newly-named Klebsiella aerogenes (formerly Enterobacter aerogenes) is Associated with Poor Clinical Outcomes Relative to other Enterobacter Species in Patients with Bloodstream Infection. *J Clin Microbiol* 2020.

7. Weinstein MP, Lewis JS. The clinical and laboratory standards institute subcommittee on antimicrobial susceptibility testing: background, organization, functions, and processes. *Journal of clinical microbiology* 2020;58.

8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-
9. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. *Clin Infect Dis* 2004;39:31-7.

10. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. *Ann Intern Med* 2002;137:791-7.

11. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005;171:388-416.

12. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. *N Engl J Med* 2020;382:1599-607.

13. Coopersmith CM, De Backer D, Deutschman CS, Ferrer R, Lat I, Machado FR, et al. Surviving sepsis campaign: research priorities for sepsis and septic shock. *Intensive Care Med* 2018;44:1400-26.

14. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009;49:1-45.

15. Huh K, Chung DR, Ha YE, Ko JH, Kim SH, Kim MJ, et al. Impact of Difficult-to-Treat Resistance in Gram-negative Bacteremia on Mortality: Retrospective Analysis of Nationwide Surveillance Data. *Clin Infect Dis* 2020;71:e487-e96.

16. Renaud B, Brun-Buisson C. Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. *Am J Respir Crit Care Med* 2001;163:1584-90.

17. Liu WY, Wong CF, Chung KM, Jiang JW, Leung FC. Comparative genome analysis of Enterobacter cloacae. *PLoS One* 2013;8:e74487.

18. Pérez A, Poza M, Fernández A, Fernández Mdel C, Mallo S, Merino M, et al. Involvement of the AcrAB-ToIC efflux pump in the resistance, fitness, and virulence of Enterobacter cloacae. *Antimicrob Agents Chemother* 2012;56:2084-90.
19. Flynn DM, Weinstein RA, Nathan C, Gaston MA, Kabins SA. Patients' endogenous flora as the source of "nosocomial" Enterobacter in cardiac surgery. *J Infect Dis* 1987;**156**:363-8.

20. Amaretti A, Righini L, Candeliere F, Musmeci E, Bonvicini F, Gentilomi GA, et al. Antibiotic Resistance, Virulence Factors, Phenotyping, and Genotyping of Non-Escherichia coli Enterobacterales from the Gut Microbiota of Healthy Subjects. *Int J Mol Sci* 2020;**21**.

21. Alammar MHM. Molecular study of some virulence factors encoding genes of Enterobacter spp. isolated from different clinical specimens. *Al-Kufa University Journal for Biology* 2013;**5**.

22. Hassan R, El-Naggar W, El-Sawy E, El-Mahdy A. Characterization of some virulence factors associated with Enterbacteriaceae isolated from urinary tract infections in Mansoura Hospitals. *Egypt J Med Microbiol* 2011;**20**:9-17.

23. Azevedo PAA, Furlan JPR, Oliveira-Silva M, Nakamura-Silva R, Gomes CN, Costa KRC, et al. Detection of virulence and β-lactamase encoding genes in Enterobacter aerogenes and Enterobacter cloacae clinical isolates from Brazil. *Braz J Microbiol* 2018;**49 Suppl 1**:224-8.

24. Goldstein FW. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. *Clin Microbiol Infect* 2002;**8**:823-5.

25. Chaubey VP, Pitout JD, Dalton B, Gregson DB, Ross T, Laupland KB. Clinical and microbiological characteristics of bloodstream infections due to AmpC β-lactamase producing Enterobacteriaceae: an active surveillance cohort in a large centralized Canadian region. *BMC Infect Dis* 2014;**14**:647.

26. Mizrahi A, Delerue T, Morel H, Le Monnier A, Carbonnelle E, Pilmis B, et al. Infections caused by naturally AmpC-producing Enterobacteriaceae: Can we use third-generation cephalosporins? A narrative review. *Int J Antimicrob Agents* 2020;**55**:105834.
Table 1. Baseline characteristics of patients with *Klebsiella aerogenes* bacteremia and patients with *Enterobacter cloacae* complex bacteremia.

| Characteristics                      | Overall                              | PS-matched                          | P     | Overall                              | PS-matched                          | P     |
|--------------------------------------|--------------------------------------|-------------------------------------|-------|--------------------------------------|-------------------------------------|-------|
|                                      | *K. aerogenes* (n = 141)              | *E. cloacae* complex (n = 141)       | **p** | *K. aerogenes* (n = 97)              | *E. cloacae* complex (n = 97)       | **p** |
| Age, years (mean ± SD) *             | 60.1 ± 14.4                         | 60.1 ± 14.4                         | 0.994 | 60.0 ± 14.2                         | 59.6 ± 14.1                         | 0.801 |
| Male sex*                            | 86 (61.0)                           | 86 (61.0)                           | > 0.999 | 58 (59.8)                           | 58 (59.8)                           | > 0.999 |
| Underlying disease                   |                                      |                                     |       |                                      |                                     |       |
| Cardiovascular disease               | 17 (12.1)                           | 20 (14.2)                           | 0.597 | 11 (11.3)                           | 12 (12.37)                          | 0.835 |
| Neurologic disease                   | 22 (15.6)                           | 16 (11.3)                           | 0.295 | 14 (14.4)                           | 11 (11.3)                           | 0.513 |
| Pulmonary disease                    | 4 (2.8)                             | 5 (3.5)                             | > 0.999 | 2 (2.1)                             | 2 (2.1)                             | > 0.999 |
| Liver disease                        | 42 (29.8)                           | 50 (35.5)                           | 0.310 | 27 (27.8)                           | 35 (36.1)                           | 0.217 |
| Renal disease                        | 29 (20.6)                           | 46 (32.6)                           | 0.022 | 26 (26.8)                           | 26 (26.8)                           | > 0.999 |
| Diabetes mellitus                    | 34 (24.1)                           | 35 (24.8)                           | 0.890 | 23 (23.7)                           | 25 (25.8)                           | 0.739 |
| Active cancer*                       | 100 (70.9)                          | 110 (78.0)                          | 0.172 | 76 (78.4)                           | 79 (81.4)                           | 0.591 |
| Transplantation*                     | 14 (9.9)                            | 21 (14.9)                           | 0.206 | 12 (12.4)                           | 13 (13.4)                           | 0.827 |
| Charlson Comorbidity Index (median, IQR) | 6 (4–9)                            | 7 (4–9)                             | 0.424 | 6 (4–9)                             | 7 (5–9)                             | 0.617 |
| Comorbid condition                   |                                      |                                     |       |                                      |                                     |       |
| Surgery within 30 days               | 30 (21.3)                           | 23 (16.3)                           | 0.286 | 19 (19.6)                           | 19 (19.6)                           | > 0.999 |
| Receipt of immunosuppressive therapy or corticosteroid within 30 days* | 44 (31.2)                           | 72 (51.1)                           | 0.001 | 38 (39.2)                           | 42 (43.3)                           | 0.450 |
| Central venous catheter              | 40 (28.4)                           | 48 (34.0)                           | 0.304 | 30 (30.9)                           | 28 (28.9)                           | 0.754 |
| Biliary drainage catheter            | 43 (30.5)                           | 35 (24.8)                           | 0.287 | 29 (29.9)                           | 27 (27.8)                           | 0.751 |
| Urinary catheter                     | 30 (21.3)                           | 17.7 (25.0)                         | 0.452 | 20 (20.6)                           | 21 (21.6)                           | 0.860 |
| ICU care*                            | 19 (13.5)                           | 12 (8.5)                            | 0.183 | 12 (12.4)                           | 11 (11.3)                           | 0.796 |
| Mechanical ventilation               | 11 (7.8)                            | 11 (7.8)                            | > 0.999 | 7 (7.2)                             | 10 (10.3)                           | 0.405 |
| Tracheostomy                         | 7 (5.0)                             | 5 (3.5)                             | 0.555 | 5 (5.2)                             | 4 (4.1)                             | 0.733 |
| Dialysis                             | 7 (5.0)                             | 11 (7.8)                            | 0.330 | 6 (6.2)                             | 8 (8.3)                             | 0.564 |
| Healthcare-associated acquisition*   | 101 (71.6)                          | 117 (83.0)                          | 0.023 | 76 (78.4)                           | 76 (78.4)                           | > 0.999 |
| Septic shock at presentation          | 36 (25.5)                           | 38 (27.0)                           | 0.787 | 25 (25.8)                           | 29 (30.0)                           | 0.505 |
| Pitt bacteremia score (median, IQR)  | 1 (0–3)                             | 1 (0–3)                             | 0.965 | 1 (0–3)                             | 1 (0–3)                             | 0.530 |
| Focus of infection                   |                                      |                                     |       |                                      |                                     |       |
| Primary bacteremia*                  | 12 (8.5)                            | 31 (22.0)                           | 0.002 | 12 (12.4)                           | 12 (12.4)                           | > 0.999 |
| Catheter related*                    | 21 (14.9)                           | 17 (12.1)                           | 0.485 | 17 (17.5)                           | 10 (10.3)                           | 0.127 |
| Respiratory tract                    | 7 (5.0)                             | 12 (8.5)                            | 0.235 | 4 (4.1)                             | 8 (8.3)                             | 0.206 |
| Hepatobiliary                        | 51 (36.2)                           | 43 (30.5)                           | 0.312 | 32 (33.0)                           | 35 (36.1)                           | 0.612 |
| Intra-abdominal                       | 20 (14.2)                           | 19 (13.5)                           | 0.863 | 15 (15.5)                           | 15 (15.5)                           | > 0.999 |
| Urinary tract*                       | 26 (18.4)                           | 13 (9.2)                            | 0.025 | 15 (15.5)                           | 13 (13.4)                           | 0.667 |
| Others                               | 5 (3.5)                             | 5 (3.5)                             | > 0.999 | 3 (3.1)                             | 3 (3.1)                             | > 0.999 |
| Appropriateness of empirical antibiotics | 107 (75.9)                          | 112 (79.4)                          | 0.475 | 78 (80.4)                           | 74 (76.3)                           | 0.480 |
| Appropriateness of definitive antibiotics | 134 (95.0)                          | 138 (97.9)                          | 0.198 | 92 (94.9)                           | 94 (96.9)                           | 0.414 |
| Definitive antibiotic regimen        | 3rd generation cephalosporin        |                                    |       |                                      |                                     |       |

Downloaded from https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab390/6324322 by guest on 26 July 2021
| Antibiotics                | Su (%) | R (%) | $p$-value | Su (%) | R (%) | $p$-value |
|---------------------------|--------|-------|-----------|--------|-------|-----------|
| 4th generation cephalosporin | 22 (15.6) | 32 (22.7) | 0.130 | 16 (16.5) | 18 (18.6) | 0.706 |
| Piperacillin/tazobactam | 32 (22.7) | 34 (24.1) | 0.778 | 23 (23.7) | 23 (23.7) | >0.999 |
| Quinolone | 32 (22.7) | 39 (27.7) | 0.337 | 20 (20.6) | 29 (29.9) | 0.137 |
| Carbapenem | 41 (29.1) | 37 (26.2) | 0.594 | 31 (32.0) | 25 (25.8) | 0.342 |
| Duration of susceptible antibiotics, days (median, IQR) | 14 (10–17) | 14 (10–17) | 0.939 | 14 (10–18) | 14 (11–18) | 0.398 |
| Source control | 101 (71.6) | 92 (65.2) | 0.249 | 57 (58.8) | 58 (59.8) | 0.884 |

### Resistance rate

| Antibiotics                | Su (%) | R (%) | $p$-value | Su (%) | R (%) | $p$-value |
|---------------------------|--------|-------|-----------|--------|-------|-----------|
| 3rd generation cephalosporin | 46 (32.6) | 37 (26.2) | 0.240 | 31 (32.0) | 26 (26.8) | 0.431 |
| 4th generation cephalosporin | 6 (4.3) | 14 (9.9) | 0.063 | 3 (3.1) | 11 (11.3) | 0.026 |
| Piperacillin/tazobactam$\textbf{a}$ | 43 (30.5) | 29 (20.6) | 0.075 | 29 (29.9) | 22 (22.9) | 0.271 |
| Imipenem | 38 (27.0) | 17 (12.1) | 0.002 | 29 (29.9) | 12 (12.4) | 0.003 |
| Azteronam | 40 (28.4) | 33 (23.4) | 0.341 | 27 (27.8) | 25 (25.8) | 0.746 |
| Ciprofloxacin$\textbf{c}$ | 4 (2.8) | 13 (9.2) | 0.021 | 2 (2.3) | 10 (10.9) | 0.022 |

**Abbreviations:** SD, standard deviation; IQR, interquartile range; ICU, intensive care unit

$\textbf{a}$ Included both bone marrow transplantation and solid organ transplantation.

$\textbf{b}$ One isolate was not tested for susceptibility to piperacillin/tazobactam.

$\textbf{c}$ Twenty-seven isolates and fifteen isolates, respectively, were not tested for susceptibility to ciprofloxacin among overall (n=205) and PS-matched (n=179) cohorts.

* Variables used for propensity score-matching
Table 2. Clinical outcomes of patients with *K. aerogenes* bacteremia and those with *E. cloacae* complex bacteremia in overall and propensity score (PS)-matched cohorts.

| Outcome                          | Overall           | *E. cloacae* Complex (n = 141) | OR (95% CI) | p    | Overall           | *E. cloacae* Complex (n = 97) | OR (95% CI) | p    |
|----------------------------------|-------------------|--------------------------------|-------------|------|-------------------|--------------------------------|-------------|------|
| 30–day all-cause mortality       | 15 (10.6)         | 34 (24.1)                      | 2.669 (1.380–5.164) | 0.003| 11 (11.3)         | 24 (24.7)                      | 2.570 (1.180–5.601) | 0.015|
| Infection attributable mortality | 6 (4.3)           | 13 (9.2)                       | 2.285 (0.843–6.194) | 0.096| 4 (4.1)           | 9 (9.3)                       | 2.378 (0.707–8.001) | 0.151|
| Treatment failure at 14 day      | 16 (11.3)         | 25 (17.7)                      | 1.684 (0.856–3.312) | 0.128| 11 (11.3)         | 18 (18.6)                      | 1.781 (0.793–4.004) | 0.159|
| Length of stay<sup>a</sup>, median, (range), day | 12 (1–1380)       | 12 (1–427)                     | 0.788       |      | 12.5 (1–225)      | 11.0 (1–427)                   | 0.751       |      |
| ICU length of stay, median, day  | 3.5 (0–1380)      | 3.0 (1–45)                     | 0.817       |      | 3.0 (0–540)       | 3.0 (0–45)                     | 0.871       |      |
| Duration of bacteremia<sup>b</sup>, median, (range), day | 2 (1–9)           | 2 (1–5)                        | 0.003       |      | 2 (1–4)           | 2 (1–5)                        | 0.661       |      |

Abbreviations: OR, odds ratio; CI, confidence interval; ICU, intensive care unit

<sup>a</sup> One patient remained admitted in the hospital until the end of this study.

<sup>b</sup> Sixty and forty-one cases for whom follow-up blood cultures were not performed within 72 hours after initial blood culture were excluded among overall (n=222) and PS-matched (n=153) cohorts.
Table 3. Patient characteristics by 30-day in-hospital mortality.

| Characteristic                        | Overall Survival (n=233) | Overall Death (n=49) | OR (95% CI) | p       | PS-matched Survival (n=159) | PS-matched Death (n=35) | OR (95% CI) | p       |
|---------------------------------------|--------------------------|----------------------|-------------|---------|-----------------------------|-------------------------|-------------|---------|
|                                       |                          |                      |             |         |                             |                         |             |         |
| **E. cloacae complex**                |                          |                      |             |         |                             |                         |             |         |
|                                       | 107 (45.9)               | 34 (69.4)            | 2.669 (1.380–5.164) | 0.003   | 73 (45.9)                   | 24 (68.6)               | 2.570 (1.180–5.601) | 0.015   |
| **Age (mean ± SD)**                   |                          |                      |             |         |                             |                         |             |         |
|                                       | 60.2 ± 14.1              | 59.2 ± 15.9          |             | 0.630   | 60.1 ± 13.4                 | 58.5 ± 17.1             |             | 0.592   |
| **Male**                              |                          |                      |             |         |                             |                         |             |         |
|                                       | 141 (60.5)               | 31 (63.3)            |             | 0.720   | 73 (45.9)                   | 24 (57.1)               |             | 0.724   |
| **Underlying disease**                |                          |                      |             |         |                             |                         |             |         |
| Cardiovascular disease                |                          |                      |             |         |                             |                         |             |         |
|                                       | 26 (11.2)                | 11 (22.4)            | 2.305 (1.051–5.054) | 0.033   | 16 (10.1)                   | 7 (20.0)               | 2.234 (0.842–5.931) | 0.107   |
| Neurologic disease                    |                          |                      |             |         |                             |                         |             |         |
|                                       | 31 (13.3)                | 7 (14.3)             | 1.086 (0.448–2.631) | 0.855   | 20 (12.6)                   | 5 (14.3)               | 1.158 (0.403–3.311) | 0.785   |
| Pulmonary disease                     |                          |                      |             |         |                             |                         |             |         |
|                                       | 8 (3.4)                  | 1 (2.0)              | 0.586 (0.072–4.795) | > 0.999 | 4 (2.5)                     | 0 (0.0)                | N/A         | N/A     |
| Liver disease                         |                          |                      |             |         |                             |                         |             |         |
|                                       | 74 (31.8)                | 18 (36.7)            | 1.248 (0.656–2.373) | 0.500   | 50 (31.4)                   | 12 (34.3)              | 1.137 (0.524–2.267) | 0.745   |
| Renal disease                         |                          |                      |             |         |                             |                         |             |         |
|                                       | 53 (22.7)                | 22 (44.9)            | 2.767 (1.458–5.253) | 0.001   | 39 (24.5)                   | 13 (37.1)              | 1.818 (0.838–3.947) | 0.131   |
| Diabetes mellitus                     |                          |                      |             |         |                             |                         |             |         |
|                                       | 58 (24.9)                | 11 (22.4)            | 0.873 (0.419–1.819) | 0.718   | 41 (25.8)                   | 7 (20.0)               | 0.720 (0.292–1.772) | 0.473   |
| Active cancer                         |                          |                      |             |         |                             |                         |             |         |
|                                       | 178 (76.4)               | 42 (85.7)            | 1.854 (0.788–4.361) | 0.152   | 125 (78.6)                  | 30 (85.7)              | 1.632 (0.589–4.525) | 0.343   |
| Transplantation *                     |                          |                      |             |         |                             |                         |             |         |
|                                       | 33 (14.2)                | 2 (4.1)              | 0.258 (0.060–1.113) | 0.052   | 23 (14.5)                   | 2 (5.7)                | 0.358 (0.080–1.597) | 0.178   |
| Charlson Comorbidity Index (median, IQR) |                          |                      |             |         |                             |                         |             |         |
|                                       | 6 (4–9)                  | 8 (6–10)             |             | 0.005   | 6 (4–9)                     | 8 (6–10)               |             | 0.082   |
| Comorbid condition                    |                          |                      |             |         |                             |                         |             |         |
| Surgery within 30 days                |                          |                      |             |         |                             |                         |             |         |
|                                       | 44 (18.9)                | 9 (18.4)             | 0.966 (0.437–2.138) | 0.933   | 32 (20.1)                   | 6 (17.1)               | 0.821 (0.314–2.146) | 0.332   |
| Receipt of immunosuppressive therapy or corticosteroid within 30 days | | | | | | | | |
|                                       | 93 (39.9)                | 23 (46.9)            | 1.332 (0.717–2.474) | 0.364   | 63 (39.6)                   | 17 (48.6)              | 1.439 (0.690–3.002) | 0.332   |
| Central venous catheter               |                          |                      |             |         |                             |                         |             |         |
|                                       | 65 (27.9)                | 23 (46.9)            | 2.286 (1.218–4.292) | 0.009   | 43 (27.0)                   | 15 (42.9)              | 2.023 (0.951–4.306) | 0.064   |
| Biliary drainage catheter             |                          |                      |             |         |                             |                         |             |         |
|                                       | 65 (27.9)                | 13 (26.5)            | 0.933 (0.465–1.872) | 0.846   | 47 (29.6)                   | 9 (25.7)               | 0.825 (0.359–1.894) | 0.649   |
| Urinary catheter                      |                          |                      |             |         |                             |                         |             |         |
|                                       | 37 (15.6)                | 18 (36.7)            | 3.076 (1.560–5.852) | 0.001   | 26 (16.4)                   | 15 (42.9)              | 3.837 (1.740–8.472) | 0.001   |
|                               | Median (IQR) | Median (IQR) | Z   | P     |
|-------------------------------|--------------|--------------|-----|-------|
| **ICU care**                  | 18 (7.7)     | 13 (26.5)    | 6.064 | < 0.001 |
| **Mechanical ventilation**    | 14 (6.0)     | 8 (16.3)     | 3.052 | 0.014    |
| **Tracheostomy**              | 10 (4.3)     | 2 (4.1)      | 0.947 | 0.947    |
| **Dialysis**                  | 11 (4.7)     | 7 (14.3)     | 3.364 | 0.013    |
| **Healthcare-associated infection** | 171 (73.4) | 47 (95.9)    | 8.520 | 0.001    |
| **Septic shock**              | 52 (22.3)    | 22 (44.9)    | 2.836 | 0.001    |
| **Pitt bacteremia score**     | 1 (0–3)      | 3 (1–4)      | < 0.001 | < 0.001 |
| **Focus of infection**        |              |              |      |        |
| **Primary bacteremia**        | 32 (13.7)    | 11 (22.4)    | 1.818 | 0.123    |
| **Catheter related**          | 32 (13.7)    | 6 (12.2)     | 0.876 | 0.781    |
| **Respiratory tract**         | 11 (4.7)     | 8 (16.3)     | 3.983 | 0.003    |
| **Hepatobiliary**             | 83 (35.6)    | 11 (22.4)    | 0.523 | 0.075    |
| **Intraabdominal**            | 31 (13.3)    | 8 (16.3)     | 1.271 | 0.578    |
| **Urinary tract**             | 35 (15.0)    | 4 (8.2)      | 0.503 | 0.206    |
| **Others**                    | 9 (3.9)      | 1 (2.0)      | 0.519 | 0.531    |
| **Inappropriateness of empirical antibiotics** | 51 (21.9) | 12 (24.5)    | 1.157 | 0.691    |
| **Inappropriateness of definitive antibiotics** | 6 (2.6) | 4 (8.2)      | 3.363 | 0.055    |
| **Definitive antibiotic regimen** |            |              |      |        |
| **3rd generation cephalosporin** | 22 (9.4) | 3 (6.1)      | 0.625 | 0.588    |
| **4th generation cephalosporin** | 47 (20.2) | 7 (14.3)     | 0.660 | 0.341    |
| **Piperacillin/tazobactam**   | 51 (21.9)    | 15 (30.6)    | 1.574 | 0.190    |
### Resistance rate

| Antibiotic Family | No. Tested (%) | Susceptible (No. (IQR)) | P-Value | No. Treated (%) | Susceptible (No. (IQR)) | P-Value |
|-------------------|----------------|-------------------------|---------|----------------|-------------------------|---------|
| Quinolone         |                |                         |         |                |                          |         |
|                   | 59 (25.3)      | 12 (24.5)               | 0.956 (0.468–1.955) | 0.903 | 41 (25.8)      | 8 (22.9) | 0.853 (0.359–2.026) | 0.718 |
| Carbapenem        | 61 (26.2)      | 17 (34.7)               | 1.498 (0.777–2.889) | 0.226 | 41 (25.8)      | 15 (42.9) | 2.159 (1.012–4.606) | 0.044 |
| **Duration of susceptible antibiotics, days (median, IQR)** |                |                         |         |                |                          |         |
|                   | 14 (11–18)     | 11 (5–16)               | 0.464 |         | 14 (11–19)     | 12 (6–16) | 0.020 |
| Source control    | 165 (70.8)     | 28 (57.1)               | 0.549 (0.292–1.034) | 0.061 | 95 (59.7)      | 20 (57.1) | 0.898 (0.428–1.884) | 0.776 |
| **Resistance rate** |                |                         |         |                |                          |         |
| **3rd generation cephalosporin** |                |                         |         |                |                          |         |
|                   | 69 (29.6)      | 14 (28.6)               | 0.951 (0.481–1.878) | 0.884 | 47 (29.6)      | 10 (28.6) | 0.953 (0.425–2.140) | 0.907 |
| **4th generation cephalosporin** |                |                         |         |                |                          |         |
|                   | 15 (6.4)       | 5 (10.2)                | 1.652 (0.571–4.780) | 0.360 | 42 (26.4)      | 9 (26.5)  | 1.923 (0.566–6.528) | 0.286 |
| **Piperacillin/tazobactam** |                |                         |         |                |                          |         |
|                   | 60 (25.8)      | 12 (24.5)               | 0.961 (0.470–1.967) | 0.232 | 36 (22.6)      | 5 (14.3)  | 1.003 (0.433–2.322) | 0.995 |
| **Imipenem**      |                |                         |         |                |                          |         |
|                   | 47 (20.2)      | 8 (16.3)                | 0.772 (0.339–1.757) | 0.537 | 36 (22.6)      | 5 (14.3)  | 0.569 (0.206–1.574) | 0.273 |
| **Azteronam**     |                |                         |         |                |                          |         |
|                   | 59 (25.3)      | 14 (28.6)               | 1.180 (0.594–2.344) | 0.637 | 42 (26.4)      | 10 (28.6) | 1.114 (0.494–2.514) | 0.794 |
| **Ciprofloxacin** | 11 (4.7)       | 6 (12.2)                | 2.783 (0.972–7.972) | 0.130 | 7 (4.8)        | 5 (15.2)  | 3.546 (1.050–11.979) | 0.047 |

Abbreviations: SD, standard deviation; IQR, interquartile range; ICU, intensive care unit

- **a** Included both bone marrow transplantation and solid organ transplantation.
- **b** One isolate was not tested for susceptibility to piperacillin/tazobactam.
- **c** Twenty-seven isolates and fifteen isolates, respectively, were not tested for susceptibility to ciprofloxacin among overall (n=205) and PS-matched (n=179) cohorts.
Table 4. Multivariable logistic regression analysis for the risk factors associated with 30-day all-cause mortality.

| Risk factor                | Overall                        |            | PS-matched                  |            |
|----------------------------|--------------------------------|------------|-----------------------------|------------|
|                            | Adjusted OR (95% CI)           | p          | Adjusted OR (95% CI)        | p          |
| E. cloacae complex         | 3.528 (1.614–7.714)            | 0.002      | 4.135 (1.619–10.558)        | 0.003      |
| Underlying renal disease   | 2.360 (1.151–4.839)            | 0.019      |                             |            |
| Transplantation a           | 0.167 (0.034–0.813)            | 0.027      | 0.167 (0.028–0.984)         | 0.048      |
| ICU care                   | 3.070 (1.170–8.052)            | 0.023      | 8.504 (1.182–61.200)        | 0.034      |
| Pitt bacteremia score      | 1.364 (1.142–1.629)            | 0.001      | 1.453 (1.170–1.803)         | 0.001      |

Abbreviations: OR, odds ratio; CI, confidence interval; ICU, intensive care unit.

a Included both bone marrow transplantation and solid organ transplantation.
Figure 1

(A) Survival probability vs. Days after bloodstream infection for K. aerogenes and E. Cloacae complex.

(B) Survival probability vs. Days after bloodstream infection for K. aerogenes and E. Cloacae complex.

Numbers at risk:

|               | K. aerogenes | E. Cloacae complex |
|---------------|--------------|--------------------|
| Days          | 141          | 131                |
| 0             | 128          | 131                |
| 5             | 105          | 99                 |
| 10            | 86           | 84                 |
| 15            | 82           | 73                 |
| 20            | 74           | 69                 |
| 25            | 68           | 59                 |
| 30            | 68           | 49                 |

P values:
P = 0.0016
P = 0.0063